Public Employees Retirement System of Ohio grew its stake in shares of Zoetis Inc (NYSE:ZTS) by 20.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 351,397 shares of the company’s stock after acquiring an additional 60,787 shares during the period. Public Employees Retirement System of Ohio owned about 0.07% of Zoetis worth $29,936,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ZTS. Polen Capital Management LLC raised its stake in shares of Zoetis by 125.3% during the first quarter. Polen Capital Management LLC now owns 8,943,633 shares of the company’s stock valued at $746,883,000 after acquiring an additional 4,974,081 shares in the last quarter. Amundi Pioneer Asset Management Inc. increased its holdings in Zoetis by 319.9% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 2,768,388 shares of the company’s stock valued at $231,187,000 after buying an additional 2,109,036 shares during the period. Banque Pictet & Cie SA increased its holdings in Zoetis by 5,516.1% during the second quarter. Banque Pictet & Cie SA now owns 1,679,617 shares of the company’s stock valued at $143,087,000 after buying an additional 1,649,710 shares during the period. Janus Henderson Group PLC increased its holdings in Zoetis by 22.3% during the second quarter. Janus Henderson Group PLC now owns 5,410,040 shares of the company’s stock valued at $460,890,000 after buying an additional 985,586 shares during the period. Finally, Bank of Montreal Can increased its holdings in Zoetis by 190.7% during the second quarter. Bank of Montreal Can now owns 1,327,357 shares of the company’s stock valued at $113,078,000 after buying an additional 870,807 shares during the period. 89.76% of the stock is owned by hedge funds and other institutional investors.

In other news, insider Roxanne Lagano sold 2,000 shares of Zoetis stock in a transaction on Monday, October 1st. The shares were sold at an average price of $92.03, for a total transaction of $184,060.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kristin C. Peck sold 5,000 shares of Zoetis stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $86.22, for a total transaction of $431,100.00. The disclosure for this sale can be found here. Insiders sold 213,467 shares of company stock worth $19,502,725 over the last ninety days. Corporate insiders own 0.35% of the company’s stock.

NYSE ZTS traded up $1.90 on Friday, hitting $88.90. The stock had a trading volume of 2,205,470 shares, compared to its average volume of 2,533,965. The company has a current ratio of 4.38, a quick ratio of 2.92 and a debt-to-equity ratio of 2.50. Zoetis Inc has a 52-week low of $63.03 and a 52-week high of $94.31. The firm has a market capitalization of $44.12 billion, a P/E ratio of 37.04, a P/E/G ratio of 1.74 and a beta of 1.01.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 2nd. The company reported $0.77 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.06. Zoetis had a net margin of 19.95% and a return on equity of 72.30%. The business had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.38 billion. During the same period in the previous year, the company earned $0.53 earnings per share. The business’s revenue for the quarter was up 11.5% on a year-over-year basis. As a group, sell-side analysts predict that Zoetis Inc will post 3.07 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Tuesday, November 20th will be issued a $0.126 dividend. This represents a $0.50 annualized dividend and a yield of 0.57%. The ex-dividend date is Monday, November 19th. Zoetis’s dividend payout ratio is currently 20.83%.

Several equities analysts recently issued reports on the stock. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and set a $95.00 price objective on the stock. in a report on Tuesday, August 21st. They noted that the move was a valuation call. Zacks Investment Research lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Cantor Fitzgerald reissued a “buy” rating and set a $98.00 price objective on shares of Zoetis in a report on Monday, October 1st. Morgan Stanley lifted their price objective on shares of Zoetis from $87.00 to $92.00 and gave the company a “hold” rating in a report on Friday, August 3rd. Finally, Argus lifted their price objective on shares of Zoetis from $90.00 to $103.00 and gave the company a “buy” rating in a report on Tuesday, August 14th. Eight equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $91.73.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Article: 52-Week High/Low

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.